Glatt Adds cGMP Manufacturing Capacity at NJ Facility

Glatt Pharmaceutical Services has added new commercial scale cGMP contract manufacturing capacity at its 86,000-sq.-ft. facility in NJ for tablet and capsule production. Added production capabilities include: high shear wet and fluid bed granulating/drying, tablet compression and pan coating, Wurster HS pelletizing and coating, CPS technology direct pelletizing, oven tray drying/curing, blending, milling, sieving and QC. Additional capabilities include organic solvent or aqueous and DEA controlled substance (CII – CV).

“We’ve made this investment in commercial scale operations in order to provide our clients the speed-to-market and high quality standards demanded in today’s competitive market,” said Oliver Mueller, executive vice president business development, Glatt Pharmaceutical Services.@font-face { font-family: “Arial”; }@font-face { font-family: “Optima”; }p.MsoNormal, li.MsoNormal, div.MsoNormal { margin: 0in 0in 0.0001pt; font-size: 10pt; font-family: Arial; }div.Section1 { page: Section1; }